What the evidence can support
BPC-157 has a substantial preclinical literature, but the central dosage question requires controlled human pharmacology and dose-ranging studies. Those data are not available at a level that supports a general schedule.
Why online schedules overstate certainty
- They often extrapolate from animal models without validated human conversion.
- They combine different routes and formulations as if they were equivalent.
- They rarely establish product identity, purity, sterility, or stability.
What this evidence review covers
Explain that controlled human evidence does not establish a BPC-157 dosage schedule.
- What the two-person IV pilot did and did not test
- Why route and formulation matter
- Animal exposure is not a human conversion
- Why BPC/TB stacks are unsupported
- Evidence gaps
Source-backed findings
Each claim below is tied to the evidence class that can support it. Commercial listing data and clinical evidence remain separate.
direct human evidence
The human pilot was n=2, uncontrolled, short-term, and not an efficacy trial.
regulatory
FDA lacks sufficient route-specific safety information to know whether compounded BPC-157 would cause harm.
| Evidence class | What the source supports |
|---|---|
| direct human evidence | The human pilot was n=2, uncontrolled, short-term, and not an efficacy trial. |
| regulatory | FDA lacks sufficient route-specific safety information to know whether compounded BPC-157 would cause harm. |
Source-by-source evidence notes
These notes state what each inspected source can support and the boundary that should not be crossed when interpreting it.
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
Evidence class: primary uncontrolled human pilot. What it supports: Two previously exposed adults; short-term vital-sign and laboratory observations; no efficacy endpoint.
What it does not establish: General safety, any efficacy claim, a dosage schedule, a monitoring protocol, or other routes.
FDA bulk substances that may present significant safety risks
Evidence class: primary regulatory. What it supports: FDA's BPC-157, injectable GHK-Cu, and TB-500 fragment safety/characterization statements; no identified human TB-500 fragment exposure data.
What it does not establish: A diagnosis, individual risk estimate, or claim that topical GHK-Cu and injectable GHK-Cu share one risk profile.
Questions this page answers
What is the standard BPC-157 dose?
No validated standard human efficacy dose was established by the inspected evidence.
Can I combine BPC-157 and TB-500?
No combination protocol is supported; the entities and evidence gaps must remain separate.
What remains unresolved
- No controlled dose-ranging human trial.
- No validated oral/injectable equivalence.
- No stack evidence.